CRISPR Knockout Screening
Benefit from 10 years experience
CRISPR genome editing provides a highly efficient way to find drug targets and probe gene function through the generation of gene knockouts.
Horizon’s CRISPR KO screening service uses a high performance all-in-one vector system. This system offers improved performance in a rapid workflow (Cross et al., 2016). Our optimized screening platform, sophisticated bioinformatics analysis, and multiple ready-made and custom libraries, allow us to design the most appropriate workflow for your screening project, providing you with data of exceptional quality.
Our platform leverages cutting edge formats and capabilities to advance and accelerate your drug development programs by offering the highest quality and greatest confidence in your screening results. Partnering with you to achieve your research vision.
CRISPR KO screens are ideally suited to:
- Identify and prioritize drug targets
- Find genes required for cell viability, drug sensitivity or resistance
- Guide patient selection for clinical trial
- Identify targets or pathways for potential combination therapies
CRISPR KO Screening Platform
Horizon can provide complete workflows for CRISPR knockout screens, from cell line selection and optimization through to bioinformatics analysis of the screen results.
Turnaround time: 12-20 weeks
Deliverables: Data in raw and analysed form and a final report containing experimental details and hit nominations
Select one of our off-the shelf sgRNA libraries or have us design a custom library!
- Cell surface, Signalling & Metabolic
- Deubiquitinases & Drug Targets
- Kinases & DNA Damage Response
- Epigenetics & Autophagy
- GeCKOv2 whole genome library
To learn more about our CRISPR screening platform, watch our recorded webinar:
Screens in primary immune cells:
CRISPR screens in primary T lymphocytes have been difficult to carry out due to the complexity of introducing screening reagents, Cas9 in particular.
Find out how Horizon scientists overcame these difficulties and successfully carried out pooled CRISPR screening in human primary T cells:
Case study: Whole genome CRISPR KO resistance screen in A375 melanoma cells
Purpose: A proof of concept study to identify resistance factors against a BRAF kinase inhibitor Vemurafenib (PLX-4032) in A375 melanoma cells that carry a BRAF V600E gain-of-function mutation.
- Pooled-based approach: lentivirus transduction of the library into cells with antibiotic selection
- Treatment of the edited cell population with Vemurafenib for 14 days
- Cell pellet collection and sample preparation
- Next-generation sequencing and data analysis using an adapted MAGeCK workflow
- Highest ranking genes were MED12, NF1, CUL3, NF2, TADA2B and TADA1, which are known to confer resistance to Vemurafenib.1
- Additional hits include members of the STAGA histone acetyl transferase complex (TAFL5/PAF65b) and the Mediator complex (MED23).
Figure 1. Ranking of the hits of the screen by MAGeCK algorithm
Download the complete application note:
Get expert advice and help for your next CRISPR screening project: